These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 33276565)

  • 21. Variance based global sensitivity analysis of physiologically based pharmacokinetic absorption models for BCS I-IV drugs.
    Melillo N; Aarons L; Magni P; Darwich AS
    J Pharmacokinet Pharmacodyn; 2019 Feb; 46(1):27-42. PubMed ID: 30552544
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In Vitro, in Silico, and in Vivo Assessments of Intestinal Precipitation and Its Impact on Bioavailability of a BCS Class 2 Basic Compound.
    Kou D; Zhang C; Yiu H; Ng T; Lubach JW; Janson M; Mao C; Durk M; Chinn L; Winter H; Wigman L; Yehl P
    Mol Pharm; 2018 Apr; 15(4):1607-1617. PubMed ID: 29522347
    [TBL] [Abstract][Full Text] [Related]  

  • 23. pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery.
    Varma MV; Gardner I; Steyn SJ; Nkansah P; Rotter CJ; Whitney-Pickett C; Zhang H; Di L; Cram M; Fenner KS; El-Kattan AF
    Mol Pharm; 2012 May; 9(5):1199-212. PubMed ID: 22489626
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of five active ingredients of Er-Zhi-Wan, a traditional Chinese medicine water-honeyed pill, using the biopharmaceutics classification system.
    Cao X; Li H; Wang M; Ren X; Deng Y
    Biomed Chromatogr; 2020 Feb; 34(2):e4757. PubMed ID: 31755125
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An in silico approach to determine challenges in the bioavailability of ciprofloxacin, a poorly soluble weak base with borderline solubility and permeability characteristics.
    Hansmann S; Miyaji Y; Dressman J
    Eur J Pharm Biopharm; 2018 Jan; 122():186-196. PubMed ID: 29111469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of Physiologically Based Pharmacokinetic Models to Predict the Absorption of BCS Class I Drugs in Different Pediatric Age Groups.
    Liu XI; van den Anker JN; Burckart GJ; Dallmann A
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S94-S107. PubMed ID: 34185902
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro solubility, dissolution and permeability studies combined with semi-mechanistic modeling to investigate the intestinal absorption of desvenlafaxine from an immediate- and extended release formulation.
    Franek F; Jarlfors A; Larsen F; Holm P; Steffansen B
    Eur J Pharm Sci; 2015 Sep; 77():303-13. PubMed ID: 26091569
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Provisional classification and in silico study of biopharmaceutical system based on caco-2 cell permeability and dose number.
    Pham-The H; Garrigues T; Bermejo M; González-Álvarez I; Monteagudo MC; Cabrera-Pérez MÁ
    Mol Pharm; 2013 Jun; 10(6):2445-61. PubMed ID: 23675957
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan.
    Takagi T; Ramachandran C; Bermejo M; Yamashita S; Yu LX; Amidon GL
    Mol Pharm; 2006; 3(6):631-43. PubMed ID: 17140251
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is the full potential of the biopharmaceutics classification system reached?
    Bergström CA; Andersson SB; Fagerberg JH; Ragnarsson G; Lindahl A
    Eur J Pharm Sci; 2014 Jun; 57():224-31. PubMed ID: 24075971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Physiologically based biopharmaceutics modeling of regional and colon absorption in humans.
    Tannergren C; Jadhav H; Eckernäs E; Fagerberg J; Augustijns P; Sjögren E
    Eur J Pharm Biopharm; 2023 May; 186():144-159. PubMed ID: 37028605
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Role of Paracellular Transport in the Intestinal Absorption and Biopharmaceutical Characterization of Minoxidil.
    Markovic M; Zur M; Garsiani S; Porat D; Cvijić S; Amidon GL; Dahan A
    Pharmaceutics; 2022 Jun; 14(7):. PubMed ID: 35890257
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Viscosity-mediated negative food effect on oral absorption of poorly-permeable drugs with an absorption window in the proximal intestine: In vitro experimental simulation and computational verification.
    Cvijić S; Parojčić J; Langguth P
    Eur J Pharm Sci; 2014 Sep; 61():40-53. PubMed ID: 24751672
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Physiologically Based Biopharmaceutics Modeling of Regional and Colon Absorption in Dogs.
    Eckernäs E; Tannergren C
    Mol Pharm; 2021 Apr; 18(4):1699-1710. PubMed ID: 33720733
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A combined in vitro in-silico approach to predict the oral bioavailability of borderline BCS Class II/IV weak base albendazole and its main metabolite albendazole sulfoxide.
    Pettarin M; Bolger MB; Chronowska M; Kostewicz ES
    Eur J Pharm Sci; 2020 Dec; 155():105552. PubMed ID: 32937212
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs.
    Dahan A; Miller JM; Amidon GL
    AAPS J; 2009 Dec; 11(4):740-6. PubMed ID: 19876745
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Physicochemical profiling (solubility, permeability and charge state).
    Avdeef A
    Curr Top Med Chem; 2001 Sep; 1(4):277-351. PubMed ID: 11899112
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification.
    Kasim NA; Whitehouse M; Ramachandran C; Bermejo M; Lennernäs H; Hussain AS; Junginger HE; Stavchansky SA; Midha KK; Shah VP; Amidon GL
    Mol Pharm; 2004 Jan; 1(1):85-96. PubMed ID: 15832504
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PBPK models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
    Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regional intestinal drug permeation: biopharmaceutics and drug development.
    Lennernäs H
    Eur J Pharm Sci; 2014 Jun; 57():333-41. PubMed ID: 23988845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.